Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | PDE9A | O76083 | 3/20 | 0.33 |
| ▸ | PDE1A | P54750 | 3/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374247 | 0.92 | SORT1 (0.36) | GPR84PDE3BPDE3APDE9APDE1A | |
| SCHEMBL6374281 | 0.86 | GPR84 (0.40) | GPR84PDE3BPDE3APARP1 | |
| SCHEMBL6370949 | 0.85 | GLA (0.41) | PDE3BPDE3APDE9APDE1APDE1B | |
| SCHEMBL6373595 | 0.83 | TSHR (0.45) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6373585 | 0.81 | ADORA3 (0.41) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366982 | 0.81 | DAO (0.50) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6365631 | 0.77 | PDE9A (0.38) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6367335 | 0.76 | PDE9A (0.36) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6367635 | 0.74 | HTT (0.41) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6371045 | 0.74 | PDE9A (0.46) | PDE9APDE1APDE1BPDE1CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | GPR84 534/4885PDE3B 6/4885PDE3A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.